Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN®
Pilot program to be initiated in four U.S. cities leveraging radio, print and social media channels, with potential for future expansion
ILUVIEN’s CONTINUOUS MICRODOSING™ delivery enables patients diagnosed with diabetic macular edema (DME) to maintain vision longer with fewer intra-ocular injections
The Company will utilize digital, radio, and in-office marketing programs highlighting the benefits of ILUVIEN in addressing challenges faced by patients with DME. The initial DTP campaign will pilot in four U.S. cities, with potential for future expansion as determined by the Company. Interested parties can access the radio spot here.
With its patented and proprietary CONTINUOUS MICRODOSING™ technology, ILUVIEN is a sustained-release intravitreal implant that is administered directly into the eye to control the recurrence of DME. In clinical trials, ILUVIEN has demonstrated the ability to reduce edema in the retina for up to 36 months with one intra-ocular injection, thereby enabling patients to maintain vision longer with fewer injections.
“We believe ILUVIEN is extremely attractive to patients suffering from DME, according to our research,” said
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period, approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING™ technology, ILUVIEN is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to control the recurrence of disease, enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S.,
See www.ILUVIEN.com for important safety information.
Alimera, founded in
Forward Looking Statements
This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s belief that the DTP pilot will be effective with patients and that increased awareness will have the intended effect. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change either of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors that could cause actual results to differ include, but are not limited to, other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended
|For press inquiries:||For investor inquiries:|
|Jules Abraham||Scott Gordon|
|for Alimera Sciences||for Alimera Sciences|
Source: Alimera Sciences, Inc.